Tomohisa Okamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomohisa Okamura has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Keishi Fujio
Department of Allergy and Rheumatology, Graduate School of Medicine, the University of Tokyo, Tokyo, Japan
5 shared publications - Hirofumi Shoda
Department of Rheumatology, Tokyo Medical University Hospital, Tokyo, Japan
2 shared publications - Kazuhiko Yamamoto
RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
2 shared publications - Kazuyoshi Ishigaki
Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
2 shared publications - Masahiro Nakano
Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
2 shared publications Mineto Ota
Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo , Tokyo
2 shared publications
Latest Publications
- Open Access
- 12 July 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (12) , 6099-6105
Stratification of systemic lupus erythematosus with IGHV4-34 in unswitched memory B cells
Objectives: SLE is an autoimmune disease characterized by the production of autoantibodies. Antibody affinities are defined by immunoglobulins, which include the immunoglobulin heavy-chain variable region (IGHV) genes, but the relationship between SLE and IGHV has not been fully elucidated. This study aimed to investigate the association between clinical features of SLE and IGHV. Methods: We recruited SLE patients and collected their peripheral blood. B cells from SLE patients were sorted into naïve B cells, unswitched memory (USM) B cells, switched memory B cells, double-negative B cells and plasmablasts. RNA-seq was performed to analyse IGHV gene usage, calculating the frequency of clonotypes that use IGHV4-34. The interactions between IGHV4-34 usage and clinical features were analysed by regression analysis, and the threshold for stratifying SLE patients by IGHV4-34 usage was determined by receiver operating characteristic (ROC) analysis. Results: IGHV4-34 usage in USM B cells had a significant association with disease activity. ROC curve analysis revealed the threshold of IGHV4-34 usage in USM B cells which distinguished patients with low complement levels from the other patients. High IGHV4-34 usage in USM B cells was associated with arthritis, haematuria, proteinuria, rash and fever. Achievement of a lupus low disease activity state (LLDAS), SLEDAI 2000 score and physician global assessment score showed worse values in the high IGHV4-34 usage group. Among those who achieved LLDAS under tacrolimus treatment, patients with high IGHV4-34 usage in USM B cells had a higher flare rate. Conclusion: IGHV4-34 usage in USM B cells is a potential biomarker of SLE and for patient stratification.
- 12 July 2025
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (12) , 6099-6105
Open AccessStratification of systemic lupus erythematosus with IGHV4-34 in unswitched memory B cells
Objectives: SLE is an autoimmune disease characterized by the production of autoantibodies. Antibody affinities are defined by immunoglobulins, which include the immunoglobulin heavy-chain variable region (IGHV) genes, but the relationship between SLE and IGHV has not been fully elucidated. This study aimed to investigate the association between clinical features of SLE and IGHV. Methods: We recruited SLE patients and collected their peripheral blood. B cells from SLE patients were sorted into naïve B cells, unswitched memory (USM) B cells, switched memory B cells, double-negative B cells and plasmablasts. RNA-seq was performed to analyse IGHV gene usage, calculating the frequency of clonotypes that use IGHV4-34. The interactions between IGHV4-34 usage and clinical features were analysed by regression analysis, and the threshold for stratifying SLE patients by IGHV4-34 usage was determined by receiver operating characteristic (ROC) analysis. Results: IGHV4-34 usage in USM B cells had a significant association with disease activity. ROC curve analysis revealed the threshold of IGHV4-34 usage in USM B cells which distinguished patients with low complement levels from the other patients. High IGHV4-34 usage in USM B cells was associated with arthritis, haematuria, proteinuria, rash and fever. Achievement of a lupus low disease activity state (LLDAS), SLEDAI 2000 score and physician global assessment score showed worse values in the high IGHV4-34 usage group. Among those who achieved LLDAS under tacrolimus treatment, patients with high IGHV4-34 usage in USM B cells had a higher flare rate. Conclusion: IGHV4-34 usage in USM B cells is a potential biomarker of SLE and for patient stratification.
- Open Access
- 8 November 2024
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 37 (4) , 189-194
The role of polyreactive memory B cells in systemic lupus erythematosus
In systemic lupus erythematosus (SLE), the production of autoantibodies is a crucial characteristic, and B cells play a significant role in its pathogenesis. B cells are the immune cells most associated with the genetic predispositions of SLE, and recent clinical studies showing that anti-CD19 chimeric antigen receptor (CAR)-T cell therapy induces drug-free remission have underscored the importance of B cells in SLE. Meanwhile, various B-cell subsets exist across different stages of differentiation, from naive B cells to plasma cells, and identifying the important subpopulations within SLE remains a critical future challenge. Years of B-cell repertoire analyses have revealed the importance of polyreactive B-cell receptors (BCRs) and autoantibodies that react to various self-antigens and microbial antigens. Particularly, memory B cells with polyreactive BCRs, which play a crucial role in biological defense during the fetal stage, are characteristically differentiated in SLE. Type I interferon-mediated expression of CXCL13 and IL-21 in CD4+ T cells is associated with the development of polyreactive memory B cells. The expansion of the polyreactive B-cell repertoire, vital for defending against infections such as viruses, may exert an intrinsic function in SLE.
- 8 November 2024
- Published by Oxford University Press (OUP) in International Immunology
- Vol. 37 (4) , 189-194
Open AccessThe role of polyreactive memory B cells in systemic lupus erythematosus
In systemic lupus erythematosus (SLE), the production of autoantibodies is a crucial characteristic, and B cells play a significant role in its pathogenesis. B cells are the immune cells most associated with the genetic predispositions of SLE, and recent clinical studies showing that anti-CD19 chimeric antigen receptor (CAR)-T cell therapy induces drug-free remission have underscored the importance of B cells in SLE. Meanwhile, various B-cell subsets exist across different stages of differentiation, from naive B cells to plasma cells, and identifying the important subpopulations within SLE remains a critical future challenge. Years of B-cell repertoire analyses have revealed the importance of polyreactive B-cell receptors (BCRs) and autoantibodies that react to various self-antigens and microbial antigens. Particularly, memory B cells with polyreactive BCRs, which play a crucial role in biological defense during the fetal stage, are characteristically differentiated in SLE. Type I interferon-mediated expression of CXCL13 and IL-21 in CD4+ T cells is associated with the development of polyreactive memory B cells. The expansion of the polyreactive B-cell repertoire, vital for defending against infections such as viruses, may exert an intrinsic function in SLE.
- Open Access
- 3 June 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-16
Egr2 drives the differentiation of Ly6Chi monocytes into fibrosis-promoting macrophages in metabolic dysfunction-associated steatohepatitis in mice
Metabolic dysfunction-associated steatohepatitis (MASH), previously called non-alcoholic steatohepatitis (NASH), is a growing concern worldwide, with liver fibrosis being a critical determinant of its prognosis. Monocyte-derived macrophages have been implicated in MASH-associated liver fibrosis, yet their precise roles and the underlying differentiation mechanisms remain elusive. In this study, we unveil a key orchestrator of this process: long chain saturated fatty acid-Egr2 pathway. Our findings identify the transcription factor Egr2 as the driving force behind monocyte differentiation into hepatic lipid-associated macrophages (hLAMs) within MASH liver. Notably, Egr2-deficiency reroutes monocyte differentiation towards a macrophage subset resembling resident Kupffer cells, hampering hLAM formation. This shift has a profound impact, suppressing the transition from benign steatosis to liver fibrosis, demonstrating the critical pro-fibrotic role played by hLAMs in MASH pathogenesis. Long-chain saturated fatty acids that accumulate in MASH liver emerge as potent inducers of Egr2 expression in macrophages, a process counteracted by unsaturated fatty acids. Furthermore, oral oleic acid administration effectively reduces hLAMs in MASH mice. In conclusion, our work not only elucidates the intricate interplay between saturated fatty acids, Egr2, and monocyte-derived macrophages but also highlights the therapeutic promise of targeting the saturated fatty acid-Egr2 axis in monocytes for MASH management.
- 3 June 2024
- Published by Springer Nature in Communications Biology
- Vol. 7 (1) , 1-16
Open AccessEgr2 drives the differentiation of Ly6Chi monocytes into fibrosis-promoting macrophages in metabolic dysfunction-associated steatohepatitis in mice
Metabolic dysfunction-associated steatohepatitis (MASH), previously called non-alcoholic steatohepatitis (NASH), is a growing concern worldwide, with liver fibrosis being a critical determinant of its prognosis. Monocyte-derived macrophages have been implicated in MASH-associated liver fibrosis, yet their precise roles and the underlying differentiation mechanisms remain elusive. In this study, we unveil a key orchestrator of this process: long chain saturated fatty acid-Egr2 pathway. Our findings identify the transcription factor Egr2 as the driving force behind monocyte differentiation into hepatic lipid-associated macrophages (hLAMs) within MASH liver. Notably, Egr2-deficiency reroutes monocyte differentiation towards a macrophage subset resembling resident Kupffer cells, hampering hLAM formation. This shift has a profound impact, suppressing the transition from benign steatosis to liver fibrosis, demonstrating the critical pro-fibrotic role played by hLAMs in MASH pathogenesis. Long-chain saturated fatty acids that accumulate in MASH liver emerge as potent inducers of Egr2 expression in macrophages, a process counteracted by unsaturated fatty acids. Furthermore, oral oleic acid administration effectively reduces hLAMs in MASH mice. In conclusion, our work not only elucidates the intricate interplay between saturated fatty acids, Egr2, and monocyte-derived macrophages but also highlights the therapeutic promise of targeting the saturated fatty acid-Egr2 axis in monocytes for MASH management.
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (93) , eadk1643
Age-associated CD4 + T cells with B cell–promoting functions are regulated by ZEB2 in autoimmunity
Aging is a significant risk factor for autoimmunity, and many autoimmune diseases tend to onset during adulthood. We conducted an extensive analysis of CD4 + T cell subsets from 354 patients with autoimmune disease and healthy controls via flow cytometry and bulk RNA sequencing. As a result, we identified a distinct CXCR3 mid CD4 + effector memory T cell subset that expands with age, which we designated “age-associated T helper (T H A) cells.” T H A cells exhibited both a cytotoxic phenotype and B cell helper functions, and these features were regulated by the transcription factor ZEB2. Consistent with the highly skewed T cell receptor usage of T H A cells, gene expression in T H A cells from patients with systemic lupus erythematosus reflected disease activity and was affected by treatment with a calcineurin inhibitor. Moreover, analysis of single-cell RNA sequencing data revealed that T H A cells infiltrate damaged organs in patients with autoimmune diseases. Together, our characterization of T H A cells may facilitate improved understanding of the relationship between aging and autoimmune diseases.
- 29 March 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 9 (93) , eadk1643
Age-associated CD4 + T cells with B cell–promoting functions are regulated by ZEB2 in autoimmunity
Aging is a significant risk factor for autoimmunity, and many autoimmune diseases tend to onset during adulthood. We conducted an extensive analysis of CD4 + T cell subsets from 354 patients with autoimmune disease and healthy controls via flow cytometry and bulk RNA sequencing. As a result, we identified a distinct CXCR3 mid CD4 + effector memory T cell subset that expands with age, which we designated “age-associated T helper (T H A) cells.” T H A cells exhibited both a cytotoxic phenotype and B cell helper functions, and these features were regulated by the transcription factor ZEB2. Consistent with the highly skewed T cell receptor usage of T H A cells, gene expression in T H A cells from patients with systemic lupus erythematosus reflected disease activity and was affected by treatment with a calcineurin inhibitor. Moreover, analysis of single-cell RNA sequencing data revealed that T H A cells infiltrate damaged organs in patients with autoimmune diseases. Together, our characterization of T H A cells may facilitate improved understanding of the relationship between aging and autoimmune diseases.
- 18 September 2022
- Published by Elsevier in Journal of Autoimmunity
- Vol. 133, 102907
Control of naive and effector CD4 T cell receptor repertoires by rheumatoid-arthritis-risk HLA alleles
- 18 September 2022
- Published by Elsevier in Journal of Autoimmunity
- Vol. 133, 102907
Control of naive and effector CD4 T cell receptor repertoires by rheumatoid-arthritis-risk HLA alleles